Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 166 Cr.
- Current Price ₹ 112
- High / Low ₹ 214 / 100
- Stock P/E 59.9
- Book Value ₹ 50.4
- Dividend Yield 0.89 %
- ROCE 6.69 %
- ROE 5.05 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 25.4%
- Company's working capital requirements have reduced from 50.2 days to 27.9 days
Cons
- Company has a low return on equity of 12.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 95.27 | 95.15 | 78.47 | 70.01 | 69.40 | |
| 74.56 | 73.69 | 65.10 | 60.78 | 60.61 | |
| Operating Profit | 20.71 | 21.46 | 13.37 | 9.23 | 8.79 |
| OPM % | 21.74% | 22.55% | 17.04% | 13.18% | 12.67% |
| 1.00 | 1.05 | 1.18 | 1.49 | 1.55 | |
| Interest | 0.17 | 0.82 | 0.83 | 1.75 | 2.48 |
| Depreciation | 1.59 | 2.04 | 2.29 | 3.21 | 3.82 |
| Profit before tax | 19.95 | 19.65 | 11.43 | 5.76 | 4.04 |
| Tax % | 25.51% | 26.92% | 26.16% | 32.12% | |
| 14.86 | 14.36 | 8.44 | 3.91 | 2.77 | |
| EPS in Rs | 10.03 | 9.70 | 5.70 | 2.64 | 1.87 |
| Dividend Payout % | 19.93% | 20.63% | 17.55% | 37.88% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -37% |
| TTM: | -62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -36% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | 39.87 | 51.60 | 57.45 | 59.81 |
| 9.75 | 14.43 | 26.46 | 42.30 | |
| 19.34 | 12.38 | 11.15 | 10.13 | |
| Total Liabilities | 83.77 | 93.22 | 109.87 | 127.05 |
| 25.49 | 33.11 | 33.09 | 77.06 | |
| CWIP | 0.00 | 0.31 | 21.06 | 1.61 |
| Investments | 7.08 | 16.79 | 19.83 | 19.83 |
| 51.20 | 43.01 | 35.89 | 28.55 | |
| Total Assets | 83.77 | 93.22 | 109.87 | 127.05 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 9.16 | 14.82 | 16.34 | 7.59 | |
| -2.64 | -20.48 | -25.89 | -2.48 | |
| 3.96 | 0.96 | 7.64 | -9.16 | |
| Net Cash Flow | 10.49 | -4.70 | -1.91 | -4.04 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 72.33 | 51.56 | 71.17 | 61.42 |
| Inventory Days | 92.33 | 124.92 | 99.63 | 135.16 |
| Days Payable | 92.57 | 71.19 | 70.84 | 60.56 |
| Cash Conversion Cycle | 72.09 | 105.28 | 99.96 | 136.01 |
| Working Capital Days | 37.43 | 67.28 | 55.49 | 27.94 |
| ROCE % | 27.63% | 13.46% | 6.69% |
Documents
Announcements
- Closure of Trading Window 2d
-
Announcement under Regulation 30 (LODR)-Change in Directorate
25 Sep - AGM on 24 Sep 2025 approved ESOP 2,000,000 options, authorized capital to Rs20 crore, director continuations.
-
1. Appointment Of Secretarial Auditor And 2. Approval Of Chemcrux Enterprises Employee Stock Option Scheme 2025 ('ESOP 2025'/'Scheme')
25 Sep - 24 Sep 2025 AGM approved Rs15Cr→Rs20Cr authorised capital, 20,00,000 ESOP options, directors' continuations.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
25 Sep - AGM (24 Sep 2025) approved Rs20 crore authorised capital, 2,000,000 ESOPs, director continuations, and secretarial auditor appointment.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep - All nine AGM resolutions passed on 24 Sep 2025, including 10% dividend, ESOP 2025, authorised capital increase.,"checklist":["Read full AGM announcement and scrutinizer report","Identify resolutions voted …
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries